Overview

A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy

Status:
Recruiting
Trial end date:
2026-06-15
Target enrollment:
Participant gender:
Summary
To learn about the safety and effects of a drug called REGN5678 when it is given to patients with high-risk prostate cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center